Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Circadian Rhythm on Glycemic Regulation During Continuous Moderate Exercise and Intense Intermittent Disease in Adolescents Living With Type 1 Diabetes

NCT06803446 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-12-18
Last updated
2025-09-04

Condition(s) studied

Type 1 Diabetes

Investigational drug(s) / intervention(s)

physical test

physical test: continuous and intermittent exercise on cycloergometer

Study summary

Interventional research with minimal risks and constraints on the effects of circadian rhythm on glycemic regulation during intense moderate, continuous and intermittent exercise in adolescents living with type 1 diabetes

Eligibility

Sex
ALL
Min age
10 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Children and adolescents aged 10 to 16; * Living with type 1 diabetes for at least 1 year with HbA1c less than or equal to 12%; * Socially insured ; * Having given their written consent to participate in the research, as well as that of their legal guardians; * Willing to comply with all research procedures and duration. Exclusion Criteria: * Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate less than 40 ml/min), neuropathy or severe proliferative retinopathy as assessed by the investigator; * Recent acute macrovascular event (\< 3 months), e.g. acute coronary syndrome or cardiac surgery; * Abnormal blood picture and/or anemia; * Current pregnancy; * Other serious medical condition likely to interfere with study participation or ability to complete exercise periods in the judgment of the investigator (e.g., orthopedic limitation); * Inability to receive informed information; * Inability to participate in the entire study; * Lack of social security coverage; * Refusal to sign the consent form.

Primary outcome measure(s)

  • Comparison of glycemic variation between the 4 conditions — 1 year 10 months september 2026
    Observation of time in target, time in hypoglycemia and time in hyperglycemia

Trial sites (1)

FacilityCityRegionStatus
Eurasport Loos Nord Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06803446 on ClinicalTrials.gov ↗ ← All trials in France